Chinese health biotech and the billion-patient market
- PMID: 18183014
- PMCID: PMC7096943
- DOI: 10.1038/nbt0108-37
Chinese health biotech and the billion-patient market
Abstract
Chinese government support and 'sea turtles' are spurring the sector, but investors lack exits.
Supplementary information: The online version of this article (doi:10.1038/nbt0108-37) contains supplementary material, which is available to authorized users.
Conflict of interest statement
Peter Singer has been the recipient of consulting funds from Merck Frosst Canada. Stephen Sammut is affiliated with Burrill & Co., an international biotechnology venture capital firm with activities in China. He does not have a direct economic stake in the firm's activities in China.
Figures



Similar articles
-
The health-care nightmare: when will we awaken?Nurs Forum. 2002 Jan-Mar;37(1):33-6. doi: 10.1111/j.1744-6198.2002.tb01189.x. Nurs Forum. 2002. PMID: 12056239 Review. No abstract available.
-
AchemAsia 2007 announcement: China's biotechnology industry on the upswing.Biotechnol J. 2007 Mar;2(3):288-90. doi: 10.1002/biot.200790029. Biotechnol J. 2007. PMID: 17354215 No abstract available.
-
Global Biotech goes China - Institut Pasteur Shanghai launches a unique platform for global biotech companies in China.Biotechnol J. 2011 Nov;6(11):1303-4. doi: 10.1002/biot.201100172. Epub 2011 Mar 24. Biotechnol J. 2011. PMID: 21438155 No abstract available.
-
Innovation drives success in Switzerland's biotech scene.Drug Discov Today. 2005 Oct 15;10(20):1342-5. doi: 10.1016/S1359-6446(05)03605-6. Drug Discov Today. 2005. PMID: 16253869 No abstract available.
-
The development of China's medical biotech industry needs to be driven by innovation.Biotechnol J. 2006 Nov;1(11):1253-7. doi: 10.1002/biot.200600086. Biotechnol J. 2006. PMID: 17068752 Review.
Cited by
-
Obstacles and opportunities in Chinese pharmaceutical innovation.Global Health. 2017 Mar 24;13(1):21. doi: 10.1186/s12992-017-0244-6. Global Health. 2017. PMID: 28340579 Free PMC article.
-
Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899862 Free PMC article.
-
Globetrotting firms: Canada's health biotechnology collaborations with developing countries.Nat Biotechnol. 2009 Sep;27(9):806-14. doi: 10.1038/nbt0909-806. Nat Biotechnol. 2009. PMID: 19741634
-
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceut Med. 2019 Aug;33(4):269-289. doi: 10.1007/s40290-019-00288-x. Pharmaceut Med. 2019. PMID: 31933185 Review.
-
Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints.Curr Opin Virol. 2015 Aug;13:33-9. doi: 10.1016/j.coviro.2015.03.009. Epub 2015 Apr 13. Curr Opin Virol. 2015. PMID: 25863716 Free PMC article. Review.
References
-
- The Economist Intelligence Unit Limited. Country Profile 2007: China. (The Economist, London, 2007).
-
- United Nations Development Program (UNDP). Human Development Report 2006. Beyond Scarcity: Power, Poverty, and the Global Water Crisis. (UNDP, New York, NY, 2006). <http://hdr.undp.org/en/reports/global/hdr2006/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical